Breaking News
Home / Business News (page 30)

Business News

Exact Sciences Strengthens Pipeline Capabilities With Acquisition of Biomatrica, A Leading Provider of Biological Sample Preservation Technology

MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica’s sample collection tubes, which contain proprietary, sample-stabilizing …

Read More »

AELIX and Gilead Collaborate to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

BARCELONA, Spain–(BUSINESS WIRE)–AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas …

Read More »

Scripps Research Translational Institute Collaborates with Seqster To Bring Genetic Risk Scores With Health Data

SAN DIEGO, Oct. 16, 2018 /PRNewswire/ — Seqster, the leading consumer-centric health data management platform empowering employees, members, or patients to collect, own and share all of their health data, today announced a collaboration with Scripps Research Translational Institute (“SRTI”), creators of the MyGeneRank app at the 2018 American Society …

Read More »

Bristol-Myers Squibb and Compugen Partner to Evaluate Therapeutic Regimen in Advanced Solid Tumors

NEW YORK & HOLON, Israel–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab), in patients with advanced …

Read More »

Ionis Enters New Collaboration with Roche to Develop IONIS-FB-L Rx for Complement-Mediated Diseases

CARLSBAD, Calif., Oct. 10, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage Ionis’ leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will …

Read More »

Biohaven Acquires Option to License the University of Connecticut’s Investigational Agent for Inflammatory and Autoimmune Diseases

NEW HAVEN, Conn., Oct. 9, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it signed an exclusive, worldwide option and license agreement with the University of Connecticut for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein (MT). Extracellular MT has been implicated in …

Read More »

Teleflex Acquires Essential Medical

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX) today announced that it has acquired Essential Medical, Inc. Based in Exton, PA, Essential Medical is a privately-held medical device company that has developed and commercialized the CE Marked MANTA™ Vascular Closure Device specifically designed for closure of large bore arteriotomies following procedures utilizing …

Read More »

Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen

PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize ARO-HBV. In addition, Arrowhead entered into a research collaboration and option agreement with Janssen …

Read More »

Kite and HiFiBiO Collaborate to Develop Technology for Potential Discovery of Neoantigen-Reactive T Cell Receptors for the Treatment of Cancer

SANTA MONICA, Calif. & HONG KONG–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery …

Read More »

Accelerated Cure Project Collaborates with EMD Serono to Advance Patient-Focused Drug Development in Multiple Sclerosis

WALTHAM, Mass., Oct. 2, 2018 /PRNewswire/ — Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) today announced it has entered into a ground-breaking collaboration with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, to capture and integrate the perspectives of people affected by …

Read More »